



Basic Annual Drug List Updates

July 2022

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
EPCLUSA (sofosbuvir-velpatasvir pellet pack 150-37.5 mg)	Brand	Addition, Preferred Status
EPCLUSA (sofosbuvir-velpatasvir pellet pack 200-50 mg)	Brand	Addition, Preferred Status
GVOKE KIT (glucagon subcutaneous soln 1 mg/0.2ml)	Brand	Addition, Preferred Status
LENVIMA 10 MG DAILY DOSE (lenvatinib cap therapy pack 10 mg (10 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 12MG DAILY DOSE (lenvatinib cap therapy pack 3 x 4 mg (12 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 14 MG DAILY DOSE (lenvatinib cap therapy pack 10 & 4 mg (14 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 18 MG DAILY DOSE (lenvatinib cap ther pack 10 mg & 2 x 4 mg (18 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 20 MG DAILY DOSE (lenvatinib cap therapy pack 2 x 10 mg (20 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 24 MG DAILY DOSE (lenvatinib cap ther pack 2 x 10 mg & 4 mg (24 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 4 MG DAILY DOSE (lenvatinib cap therapy pack 4 mg (4 mg daily dose))	Brand	Addition, Preferred Status
LENVIMA 8 MG DAILY DOSE (lenvatinib cap therapy pack 2 x 4 mg (8 mg daily dose))	Brand	Addition, Preferred Status
MAVYRET (glecaprevir-pibrentasvir pellet pack 50-20 mg)	Brand	Addition, Preferred Status
MAYZENT (siponimod fumarate tab 1 mg (base equiv))	Brand	Addition, Preferred Status
MAYZENT STARTER PACK (siponimod fumarate tab 0.25 mg (7) starter pack)	Brand	Addition, Preferred Status
NUWIQ (antihemophil fact rcmb(bdd-rfviii,sim) for inj kit 1500 unit)	Brand	Addition, Preferred Status
NUWIQ (antihemophilic fact rcmb (bdd-rfviii,sim) for inj 1500 unit)	Brand	Addition, Preferred Status
RINVOQ (upadacitinib tab er 24hr 30 mg)	Brand	Addition, Preferred Status
RINVOQ (upadacitinib tab er 24hr 45 mg)	Brand	Addition, Preferred Status
SAVELLA (milnacipran hcl tab 100 mg)	Brand	Addition, Preferred Status
SAVELLA (milnacipran hcl tab 12.5 mg)	Brand	Addition, Preferred Status
SAVELLA (milnacipran hcl tab 25 mg)	Brand	Addition, Preferred Status
SAVELLA (milnacipran hcl tab 50 mg)	Brand	Addition, Preferred Status
SAVELLA TITRATION PACK (milnacipran hcl tab 12.5 mg (5) & 25 mg (8) & 50 mg (42) pak)	Brand	Addition, Preferred Status
TAKHZYRO (lanadelumab-flyo soln pref syringe 300 mg/2ml (150 mg/ml))	Brand	Addition, Preferred Status
TALZENNA (talazoparib tosylate cap 0.5 mg (base equivalent))	Brand	Addition, Preferred Status
TALZENNA (talazoparib tosylate cap 0.75 mg (base equivalent))	Brand	Addition, Preferred Status
XARELTO (rivaroxaban for susp 1 mg/ml)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.